- Forums
- ASX - By Stock
- MSB
- Ann: Remestemcel Controlled Study in Crohns & Ulcerative Colitis
MSB
mesoblast limited
Add to My Watchlist
2.99%
!
$1.72

Ann: Remestemcel Controlled Study in Crohns & Ulcerative Colitis, page-4
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
$1.72 |
Change
0.050(2.99%) |
Mkt cap ! $2.204B |
Open | High | Low | Value | Volume |
$1.67 | $1.74 | $1.67 | $3.053M | 1.781M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
25 | 14699 | $1.72 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.73 | 38640 | 25 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
23 | 18328 | 1.715 |
19 | 41489 | 1.710 |
12 | 70372 | 1.705 |
13 | 97838 | 1.700 |
11 | 110895 | 1.695 |
Price($) | Vol. | No. |
---|---|---|
1.720 | 35115 | 26 |
1.725 | 44521 | 22 |
1.730 | 109194 | 17 |
1.735 | 132019 | 11 |
1.740 | 46765 | 12 |
Last trade - 12.25pm 15/07/2025 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |
The Watchlist
CC9
CHARIOT CORPORATION LTD
Shanthar Pathmanathan, MD
Shanthar Pathmanathan
MD
Previous Video
Next Video
SPONSORED BY The Market Online